16:35:13 Europe / Stockholm
Svenska | English

IRLAB Therapeutics

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-10-30 Kvartalsrapport 2024-Q3
2024-07-10 Kvartalsrapport 2024-Q2
2024-05-23 Ordinarie utdelning IRLAB A 0.00 SEK
2024-05-22 Årsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-02-07 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-06-21 Ordinarie utdelning IRLAB A 0.00 SEK
2023-06-20 Årsstämma 2023
2023-05-10 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-12 Ordinarie utdelning IRLAB A 0.00 SEK
2022-05-11 Kvartalsrapport 2022-Q1
2022-05-11 Årsstämma 2022
2022-02-23 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning IRLAB A 0.00 SEK
2021-05-06 Kvartalsrapport 2021-Q1
2021-05-06 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-05-08 Ordinarie utdelning IRLAB A 0.00 SEK
2020-05-07 Kvartalsrapport 2020-Q1
2020-05-07 Årsstämma 2020
2020-02-06 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-28 Split IRLAB A 1:5
2019-04-26 Ordinarie utdelning IRLAB A 0.00 SEK
2019-04-25 Kvartalsrapport 2019-Q1
2019-04-25 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-29 Kvartalsrapport 2018-Q2
2018-05-17 Ordinarie utdelning IRLAB A 0.00 SEK
2018-05-16 Kvartalsrapport 2018-Q1
2018-05-16 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-11-15 Kvartalsrapport 2017-Q3
2017-08-29 Kvartalsrapport 2017-Q2
2017-05-16 Årsstämma 2017
2017-05-16 Kvartalsrapport 2017-Q1
2017-02-27 Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
IRLAB Therapeutics är ett svenskt forsknings- och läkemedelsbolag. Forskningen utgår ifrån bolagets egna forskningsplattform och är specialiserad mot behandling av hjärnsjukdomar, vanligen benämnt neurodegenerativa sjukdomar. I nuvarande stund innehar bolaget läkemedelskandidater specialiserade mot bland annat Parkinsons sjukdom. Huvudkontoret ligger i Göteborg.
IRLAB to present the company at Redeye Neurology Seminar on October 12, 2022
2022-10-11 07:00:00

Gothenburg, Sweden, October 11, 2022 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, today announced that Richard Godfrey, CEO of IRLAB, will present the company at Redeye Neurology Seminar and participate in a panel discussion on Wednesday, October 12, 2022.

The presentation starts at 10:22 CEST and the panel discussion at 10:46 CEST on Wednesday, October 12, 2022. The event is broadcasted live via www.redeye.se/events/847068/redeye-theme-neurology#schedule, where registration for in-person attendance at the venue in central Stockholm also is available. A recording of the presentation will be made available on our company website, www.irlab.se, following the event.

For more information:

Richard Godfrey, CEO
Phone: +46 730 70 69 00
E-mail: richard.godfrey@irlab.se

About IRLAB

IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's . In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam.
 
IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB’s strong clinical pipeline, the company is also progressing two preclinical programs, IRL942 and IRL757, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.

Attachments

IRLAB to present the company at Redeye Neurology Seminar on October 12, 2022

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden